Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04273061 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity

Study acronym: CAPTIV-8
StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary endpoint reworded 1 of 1 changed
Enrollment reduced 75% 200 → 50 participants
See other at-risk trials from British Columbia Cancer Agency

Record History

  1. Primary endpoint(s) modified Enrollment reduced: 200 → 50 participants · Trial arms changed: 8 → 3 · Eligibility criteria expanded, about 52 words · 4 more Show 7 more changesShow less
    • Enrollment reduced: 200 → 50 participants
    • Trial arms changed: 8 → 3
    • Eligibility criteria expanded, about 52 words
    • Secondary endpoints revised (5)
    • Site details revised at 1 of 2 sites
    • Collaborators: 1 to 4
    • Publications: details revised at 39 of 39 entries
  2. Re-verified, no change to tracked fieldsv8
  3. Primary and study completion dates: Oct 2026 to Oct 2027 Site details revised at 1 of 2 sitesv7 Show 1 more changeShow less
    • Site details revised at 1 of 2 sites
  4. Primary and study completion dates: Oct 2024 to Oct 2026 Eligibility criteria expanded, about 61 wordsv6 Show 1 more changeShow less
    • Eligibility criteria expanded, about 61 words

    See this version in full on ClinicalTrials.gov ↗

  5. Study sites: 1 to 2v5
Show 3 earlier versionsHide 3 earlier versions
  1. Re-verified, no change to tracked fieldsv4
  2. Start date changed from estimate of Jun 2020 to Jun 17, 2020v3
  3. Trial status: Not Yet Recruiting to Recruiting Start date: Mar 2020 to Jun 2020 · Site details revisedv2 Show 2 more changesShow less
    • Start date: Mar 2020 to Jun 2020
    • Site details revised
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
British Columbia Cancer Agency
49 trials monitored
See 5 trials at risk
Breast Cancer
5,213 trials monitored
See 271 trials at risk
Lung Cancer
4,057 trials monitored
See 217 trials at risk
Head & Neck Cancer
2,060 trials monitored
See 120 trials at risk
and 1 more disease
This study will investigate the effects of atezolizumab on select cancer types in people whose analysis of tumour DNA and RNA indicates they may be sensitive to atezolizumab. This study aims to determine if the information from the cancer genome analysis corresponds with the effects of atezolizumab on individuals and their cancer. This is a Phase 2 study, which is undertaken after preliminary safety testing on a drug is completed, and will involve approximately 50 participants. Participants are assigned to one of 3 cohorts based on their primary tumour type: gastrointestinal (GI), sarcoma, and 'other' cancer types. Participants in all cohorts will receive the same dose of atezolizumab (1200 mg every 3 weeks). Participants continue on treatment until they no longer may benefit from the treatment or they decide to stop treatment.
Trial Details
NCT Number NCT04273061
Lead Sponsor British Columbia Cancer Agency
Collaborators: Hoffmann-La Roche, BC Cancer Foundation, Genome British Columbia, Terry Fox Research Institute
Conditions Breast Cancer, Lung Cancer, Gastrointestinal Cancer, Genitourinary Cancer, Gynecologic Cancer, Sarcoma, Unknown Primary Tumors, Head and Neck Cancer +1 more
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov